Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 23, 2004, Pages 5775-5780

  Cecchi, Alessandro ^a   Winum, Jean Yves ^a,b   Innocenti, Alessio ^a   Vullo, Daniela ^a   Montero, Jean Louis ^b   Scozzafava, Andrea ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYBENZOLAMIDE; 5 [4 (3 MORPHOLIN 4 YLTHIOUREIDO)BENZENESULFONYLAMINO] 1,3,4 THIADIAZOLE 2 SULFONAMIDE; 5 [4 [(3 PENTAFLUOROANILYL)THIOUREIDO]BENZENESULFONYLAMINO] 1,3,4 THIADIAZOLE 2 SULFONAMIDE; 5 [4 [3 (2 DIMETHYLAMINOETHYL)THIOUREIDO]BENZENESULFONYLAMINO] 1,3,4 THIADIAZOLE 2 SULFONAMIDE; 5 [4 [3 (2 FLUOROPHENYL)THIOUREIDO]BENZENESULFONYLAMINO] 1,3,4 THIADIAZOLE 2 SULFONAMIDE; 5 [4 [3 (2 MORPHOLIN 4 YLETHYL)THIOUREIDO]BENZENESULFONYLAMINO] 1,3,4 THIADIAZOLE 2 SULFONAMIDE; 5 [4 [3 (4 METHYLPIPERAZIN 1 YL)THIOUREIDO]BENZENESULFONYLAMINO] 1,3,4 THIADIAZOLE 2 SULFONAMIDE; ACETAZOLAMIDE; AMINOBENZOLAMIDE; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; BENZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE IX; DICLOFENAMIDE; ETHOXZOLAMIDE; METHAZOLAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG; ZINC;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOSOL; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; NONHUMAN;

BENZOLAMIDE; CARBONIC ANHYDRASE I; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CYTOSOL; HUMANS; NEOPLASMS; NERVE TISSUE PROTEINS; SULFONAMIDES;

EID: 7044241041     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.09.062     Document Type: Article

References (39)

1. C.T. Supuran A. Scozzafava J. Conway Carbonic Anhydrase†"â€"Its Inhibitors and Activators 2004 CRC (Taylor and Francis Group) Boca Raton, FL pp 1â€"376, and references cited therein
2. C.T. Supuran, and A. Scozzafava Expert Opin. Ther. Pat. 10 2000 575 600;
3. C.T. Supuran, and A. Scozzafava Expert Opin. Ther. Pat. 12 2002 217 242
4. C.T. Supuran, A. Scozzafava, and A. Casini Med. Res. Rev. 23 2003 146 189
5. A. Scozzafava, A. Mastrolorenzo, and C.T. Supuran Expert Opin. Ther. Pat. 14 2004 667 702
6. S. Pastorekova, S. Parkkila, J. Pastorek, C.T. Supuran, and J. Enzyme Inhib. Med. Chem. 19 2004 199 229
7. C.T. Supuran, D. Vullo, G. Manole, A. Casini, and A. Scozzafava Curr. Med. Chem.â€"Cardiovasc. Hematol. Agents 2 2004 49 68
8. C.T. Supuran, A. Casini, and A. Scozzafava Development of Sulfonamide Carbonic Anhydrase Inhibitors (CAIs) C.T. Supuran A. Scozzafava J. Conway Carbonic Anhydraseâ€"â€"Its Inhibitors and Activators 2004 CRC Boca Raton, FL, USA 67 148
9. T.H. Maren Physiol. Rev. 47 1967 595 781
10. S. Pastorekova, and J. Pastorek Cancer-Related Carbonic Anhydrase Isozymes C.T. Supuran A. Scozzafava J. Conway Carbonic Anhydrase†"â€"Its Inhibitors and Activators 2004 CRC Boca Raton, FL, USA 253 280
11. A. Scozzafava, T. Owa, A. Mastrolorenzo, and C.T. Supuran Curr. Med. Chem. 10 2003 925 953
12. A. Casini, A. Scozzafava, A. Mastrolorenzo, and C.T. Supuran Curr. Cancer Drug Targets 2 2002 55 75
13. F. Abbate, A. Casini, T. Owa, A. Scozzafava, and C.T. Supuran Bioorg. Med. Chem. Lett. 14 2004 217 223
14. B.A. Teicher, S.D. Liu, J.T. Liu, S.A. Holden, and T.S. Herman Anticancer Res. 13 1993 1549 1556
15. T. Owa, H. Yoshino, T. Okauchi, K. Yoshimatsu, Y. Ozawa, N.H. Sugi, T. Nagasu, N. Koyanagi, and K. Kitoh J. Med. Chem. 42 1999 3789 3799
16. A. Weber, A. Casini, A. Heine, D. Kuhn, C.T. Supuran, A. Scozzafava, and G. Klebe J. Med. Chem. 47 2004 550 557
17. S. Pastorekova, A. Casini, A. Scozzafava, D. Vullo, J. Pastorek, and C.T. Supuran Bioorg. Med. Chem. Lett. 14 2004 869 873
18. J.R. Casey, P.E. Morgan, D. Vullo, A. Scozzafava, A. Mastrolorenzo, and C.T. Supuran J. Med. Chem. 47 2004 2337 2347
19. M. Franchi, D. Vullo, E. Gallori, J. Pastorek, A. Russo, A. Scozzafava, S. Pastorekova, and C.T. Supuran J. Enzyme Inhib. Med. Chem. 18 2003 333 338
20. D. Vullo, M. Franchi, E. Gallori, J. Pastorek, A. Scozzafava, S. Pastorekova, and C.T. Supuran J. Enzyme Inhib. Med. Chem. 18 2003 403 406;
21. M.A. Ilies, D. Vullo, J. Pastorek, A. Scozzafava, M. Ilies, M.T. Caproiu, S. Pastorekova, and C.T. Supuran J. Med. Chem. 46 2003 2187 2196
22. J.-Y. Winum, D. Vullo, A. Casini, J.-L. Montero, A. Scozzafava, and C.T. Supuran J. Med. Chem. 46 2003 2197 2204
23. C.T. Supuran Expert Opin. Invest. Drugs 12 2003 283 287
24. Y. Ozawa, N.H. Sugi, T. Nagasu, T. Owa, T. Watanabe, N. Koyanagi, H. Yoshino, K. Kitoh, and K. Yoshimatsu Eur. J. Cancer 37 2001 2275 2282
25. A. Casini, A. Scozzafava, F. Mincione, L. Menabuoni, M.A. Ilies, and C.T. Supuran J. Med. Chem. 43 2000 4884 4892
26. A. Casini, A. Scozzafava, F. Mincione, L. Menabuoni, and C.T. Supuran J. Enzyme Inhib. Med. Chem. 17 2002 333 343
27. T.H. Maren Benzolamideâ€"â€"A Renal Carbonic Anhydrase Inhibitor F.E. Karch Orphan Drugs 1982 Dekker New York 89 115
28. A. Casini, A. Scozzafava, F. Mincione, L. Menabuoni, M. Starnotti, and C.T. Supuran Bioorg. Med. Chem. Lett. 13 2003 2867 2873
29. F. Abbate, A. Casini, A. Scozzafava, and C.T. Supuran Bioorg. Med. Chem. Lett. 14 2004 2357 2361
30. C.T. Supuran, M.A. Ilies, and A. Scozzafava Eur. J. Med. Chem. 33 1998 739 752
31. -
32. 26 Stock solutions of inhibitor (1 mM) were prepared in distilled-deionized water with 10-20% (v/v) DMSO (which is not inhibitory at these concentrations) and dilutions up to 0.01 nM were done thereafter with distilled-deionized water. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. Triplicate experiments were done for each inhibitor concentration, and the values reported throughout the paper are the mean of such results. The activity of these enzyme preparations seem to be rather similar with the in vivo activity of CA IX in tumors as recently proved by CA inhibitor binding studies and disturbance of tumor pH following CA IX inhibition as compared to normal tissue pH (Švastová, E.; Hulí-ková, A.; Rafajová, M.; Zat'ovicǒová, M.; Gibadulinová, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C. T.; Pastorek, J.; Pastoreková, S. FEBS Lett., in press)
33. S. Lindskog, G. Behravan, C. Engstrand, C. Forsman, B.H. Jonsson, Z. Liang, X. Ren, and Y. Xue Structure-Function Relations in Human Carbonic Anhydrase II as Studied by Site-Directed Mutagenesis F. Botrè G. Gros B.T. Storey Carbonic Anhydrase - From Biochemistry and Genetics to Physiology and Clinical Medicine 1991 VCH Weinheim 1 13
34. G. Behravan, B.H. Jonsson, and S. Lindskog Eur. J. Biochem. 190 1990 351 357
35. R.G. Khalifah, D.J. Strader, S.H. Bryant, and S.M. Gibson Biochemistry 16 1977 2241 2247
36. S. Lindskog, and J.E. Coleman Proc. Natl. Acad. Sci. U.S.A. 70 1964 2505 2508
37. H. Steiner, B.H. Jonsson, and S. Lindskog Eur. J. Biochem. 59 1975 253 259
38. J. Pastorek, S. Pastorekova, I. Callebaut, J.P. Mornon, V. Zelnik, R. Opavsky, M. Zatovicova, S. Liao, D. Portetelle, E.J. Stanbridge, J. Zavada, A. Burny, and R. Kettmann Oncogene 9 1994 2877 2888
39. R.G. Khalifah J. Biol. Chem. 246 1971 2561 2573